Following completion of her postdoctoral training, Dr. Haigwood spent 17 years in the biotechnology and pharmaceutical sector, principally at Chiron Corporation (Novartis) in Emeryville, California, and at the Bristol-Myers Squibb Pharmaceutical Research Institute in Seattle, Washington. From 1997-2007, she was a Professor of Microbiology and Pathobiology at the University of Washington and Member at the Center for Infectious Disease Research, both in Seattle. Since 1986, the focus of her research has been on HIV and AIDS, with a focus on halting mother to child transmission and on vaccines for children and adults. She was recruited to OHSU in 2007 to become the fifth director of the Oregon National Primate Research Center and a Professor of Pathobiology & Immunology to continue a highly funded research program. Dr. Haigwood served for many years as a volunteer board member for the local AIDS service organization in Portland, the Cascade AIDS Project. She is an advocate for science education and outreach to the public and frequently speaks both locally and nationally on this subject.
Areas of interest
- HIV and AIDS
- Mother to child transmission of HIV
- Nonhuman primate models for human disease
- Antibody-based therapies for infectious diseases
- Viral vaccines
- Viral pathogenesis and immunity
- Ph.D., University of North Carolina at Chapel Hill United States 1980
- Postdoctoral fellowship, Johns Hopkins University, 1979-1981
Honors and awards
- Fellow of the American Academy of Microbiology
- Australasian Society for Immunology Visiting Speaker
- Cascade AIDS Project 2017 Action Award in recognition of outstanding volunteer service to this AIDS service organization
Memberships and associations
- Associate Editor, Journal of Virology 2000-2016
- Editorial Board, AIDS, 2009-10 and 2016-present
- Office of AIDS Research Advisory Council, 2002-2005
- US-Japan Cooperative Medical Science Program (AIDS panel); retired U.S. Chairman, 2003-10
- Board of Scientific Counselors, NCI, NIH 2006-2008
- Scientific Advisory Committee, International AIDS Vaccine Initiative, 2007-2012
- Council of Councils, NIH 2013-2015
- National Association for Biomedical Research, Executive Board 2013-2016
- Board of Scientific Counselors, Vaccine Research Center, NIAID, NIH 2011-present
Steimer, KS, CJ Scandella, PV Skiles, and NL Haigwood (1991) Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254:105-108.
Igarashi T, C Brown, A Azadegan, N Haigwood, M Martin, and R Shibata. (1999) Human immunodeficiency virus type 1 neutralizing antibodies facilitate clearance of cell-free virions from blood plasma. Nature Medicine 5:211-216.
Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL (2010) Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nature Medicine 16(10):1117-9.
JP Jaworski, Z Brower, EJ Leon, DC Malherbe, G Landucci, WF Sutton, B Guo, F Engelmann, B Zheng, A Legasse, B Park, M Dickerson, AD Lewis, LMA Colgin, M Axthelm, I Messaoudi, J Kobie, JB Sacha, DR Burton, DN Forthal, AJ Hessell, and NL Haigwood (2013) Passive neutralizing antibodies alter the dynamics of infection and enhance survival of SHIVSF162P3-infected infant rhesus macaques, J Virol 87: 10447-59.
Krebs, SJ, SP McBurney, DN Kovarik, CD Waddell, JP Jaworski, WF Sutton, MM Gomes, M Trovato, G Waagmeester, SJ Barnett, P DeBerardinis, NL Haigwood (2014) Multimeric scaffolds displaying the HIV-1 Envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA. PLoS One 9: e113463. PMCID: 4267727.
Hessell AJ, DC Malherbe, F Pissani, SP McBurney, SJ. Krebs, M Gomes, S Pandey, WF Sutton, BJ Burwitz, M Gray, H Robins, B Park, JB Sacha, CC LaBranche, DH Fuller, DC Montefiori, L Stamatatos, DN Sather|, and NL Haigwood (2016) Achieving potent autologous neutralizing antibody responses against Tier 2 HIV-1 viruses by strategic selection of Envelope immunogens, Journal of Immunology 196: 3064-78.
AJ Hessell, JP Jaworski, E Epson, K Matsuda, S Pandey, C Kahl, J Reed, WF Sutton, KB Hammond, TA Cheever, PT Barnette, A Legasse, S Planer, J Stanton, A Pegu, X Chen, K Wang, MK Axthelm, A Lewis, VM Hirsch, BS Graham, JR Mascola, JB Sacha, and NL Haigwood (2016) Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Medicine 22: 362-8.
Hessell AJ, Powell R, Jiang X, Luo C, Weiss S, Dussupt V, Itri V, Fox A, Shapiro MB, Pandey S, Cheever T, Fuller DH, Park B, Krebs SJ, Totrov M, Haigwood NL, Kong XP, Zolla-Pazner S. (2019) Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. Cell Rep, Jul 23;28(4):877-895. PMC31340151
Nikzad, R, Angelo, LS, Aviles-Padilla, K, Le, DT, Singh, VK, Bimler, L., Vukmanovic-Stejic, M, Vendrame, E, Ranganath, T, Simpson, L, Haigwood, NL, Blish, CA, Akbar, AN, Paust, S. (2019) Human natural killer cells mediate adaptive immunity to viral antigens, Sci Immunol 4(35), PMC6636344.
MB Shapiro, T Cheever, DC Malherbe, S Pandey, J Reed, ES Yang, K Wang, A Pegu, X Chen, D Siess, D Burke, H Henderson, R Lewinsohn, M Fischer, JJ. Stanton, MK Axthelm, C Kahl, B Park, AD Lewis, JB Sacha, JR Mascola, AJ Hessell, NL Haigwood (2020) Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity, Nat Comm, Jan 7;11(1): 70. PMC6946664.
- "Pediatric AIDS" 2008
- "U.S.-Japan Cooperative Medical Science Program. 10th International Conference on Emerging Infectious Diseases in the Pacific Rim." Tuberculosis August 2007
- "Passive immune globulin therapy in the SIV/macaque model" Immunology Letters June 1996
- "High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection" Journal of Virology April 2009
- "Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity" Pharmaceutical Research September 1 2014
- "AIDS vaccine 2005. 6-9 September 2005, Montreal, Canada" IDrugs : the investigational drugs journal November 2005
- "Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination" Pediatric Infectious Disease Journal April 2009
- "Perinatal transmission of SHIV-SF162P3 in Macaca nemestrina" Journal of Medical Primatology October 2004
- "Protection from pathogenic SIV challenge using multigenic DNA vaccines" Immunology Letters March 1 1999
- "Update on animal models for HIV research" European Journal of Immunology August 2009
- "Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge" Journal of Virology November 2003
- "New recombinant vaccines based on the use of prokaryotic antigen-display system" Expert Review of Vaccines December 2004
- "Characterization of a CD4-Expressing Macaque Cell Line That Can Detect Virus after a Single Replication Cycle and Can Be Infected by Diverse Simian Immunodeficiency Virus Isolates" Virology November 1995
- "Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques" Journal of Virology January 2006
- "Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits" Journal of Virology 2014
- "Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles" AIDS Research and Human Retroviruses April 2004
- "Inactivated whole SIV vaccine in macaques" AIDS Research and Human Retroviruses 1992
- "DNA vaccine strategies" ImmunoMethods November 1 2003
- "B-cell abnormalities in AIDS" Scandinavian Journal of Immunology 1993
- "Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3" Journal of Virology January 2007
- "Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies" Journal of Virology June 2004
- "Host factors involved in the viral replication and particle formation could give a new insight into the innate immunity and may turn out to be a good target for therapeutic intervention. Introduction." Vaccine May 26 2010
- "Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques" AIDS Research and Human Retroviruses 1997
- "Immunization against SIVmne in macaques using multigenic DNA vaccines" Journal of Medical Primatology August 1999
- "DNA fragments of the Mus musculus Î² globin haplotypes Hbb(s) and Hbb(d)" Proceedings of the National Academy of Sciences of the United States of America 1979
- "Animal studies and HIV research  (multiple letters)" BMJ (Online) January 26 2002
- "Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially" Vaccine August 10 2012
- "Animal models in HIV-1 protection and therapy" Current Opinion in HIV and AIDS May 27 2015
- "Locations of three repetitive sequence families found in BALB/c adult Î²-globin clones" Nucleic Acids Research March 11 1981
- "Humoral immunity to HIV, SIV, and SHIV." AIDS 1998